

Advaxis, Inc.  
Form 8-K  
October 15, 2007

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**October 9, 2007**

(Date of Earliest Event Reported)

**Advaxis, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**00028489**  
(Commission  
File Number)

**02-0563870**  
(IRS Employer  
Identification No.)

**Technology Center of New Jersey  
675 Rt. 1, Suite B113  
North Brunswick, N.J. 08902**

(Address of principal executive offices)

**(732) 545-1590** (Registrant's telephone number, including area code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 8.01 Other Events**

On October 9, 2007, a press release was issued by Advaxis, Inc. (the "Registrant") (OTCBB: ADXS) reporting the results of a Phase I/II trial of Lovaxin C in advanced cervical cancer patients.

A copy of Advaxis, Inc.'s press release is attached as Exhibit 99.1

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 10, 2007

**Advaxis, Inc.**

By: /s/ Thomas A. Moore  
Name: Thomas A. Moore  
Title: Chief Executive Officer

---